Verrica Pharmaceuticals Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $5.9 million (-53.8% year over year) and diluted EPS of -$0.62. It usually reports 37–70 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–70 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
6
-53.8%
|
-13
-6547.5%
|
-0.62
-3200.0%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
5
+46.1%
|
-10
+0.6%
|
-0.45
+56.3%
|
|
Mar 11, 2026
70 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
5
+1380.2%
|
-8
+50.2%
|
-0.57
+76.2%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
14
+905.4%
|
-0
+98.8%
|
-0.03
+99.4%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
13
+145.4%
|
0
+101.2%
|
0.02
+100.5%
|
|
May 13, 2025
43 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
-10.1%
|
-10
+52.1%
|
-1.03
-134.1%
|
|
Mar 11, 2025
70 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
0
-82.7%
|
-16
+34.2%
|
-2.41
-353.1%
|
|
Nov 4, 2024
35 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
-2
-161.1%
|
-23
+7.8%
|
-4.88
-803.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRCA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- West Chester, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1660334
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.